127 filings
6-K
ARGX
Argen X SE
9 May 24
On track to submit filing for pre-filled syringe (PFS) in second quarter 2024
7:06am
6-K
ARGX
Argen X SE
8 May 24
Current report (foreign)
6:15am
6-K
ARGX
Argen X SE
16 Apr 24
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years
6:05am
6-K
ARGX
Argen X SE
27 Mar 24
Current report (foreign)
6:14am
6-K
ARGX
Argen X SE
27 Mar 24
Current report (foreign)
6:07am
6-K
8mxka2 ig8cg7i06s8
26 Mar 24
Regulatory decision in Japan represents first global approval for VYVGART in ITP
6:05am
6-K
1jkft8 yu
21 Mar 24
Current report (foreign)
6:07am
6-K
osd2hl
8 Mar 24
ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years
6:05am
6-K
evr6sm72zq 166z
29 Feb 24
Current report (foreign)
4:04pm
6-K
79z q2zl8ajf6b3
20 Feb 24
If approved, VYVGART® Hytrulo will be the first neonatal Fc receptor (FcRn) blocker to treat CIDP
6:06am
6-K
xvqo md43pk2zu
18 Jan 24
Current report (foreign)
6:10am
6-K
v4o3 6iwrxkw
8 Jan 24
Reported $1.2 billion in preliminary* full-year 2023 global net product sales
6:06am
6-K
x97nfkcx2qz2 d5ke
20 Dec 23
Current report (foreign)
6:00am
6-K
gosem9c6bb2j
28 Nov 23
Current report (foreign)
6:01am
6-K
9els79rv
17 Nov 23
VYVGART® is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in Europe
6:01am
6-K
zv8a08
1 Nov 23
Patients treated with VYVGART experienced consistent improvements on key quality of life measures based on long-term gMG extension data
4:01pm
6-K
sgs7njp1hx5dfcj
31 Oct 23
Current report (foreign)
9:14am
6-K
8jcx68
21 Sep 23
Current report (foreign)
8:38am
6-K
niw2v wtvvlzbplh
27 Jul 23
Current report (foreign)
6:02am
6-K
gttgf 7rpqr
20 Jul 23
Current report (foreign)
5:44pm